Zydus to settle Mirabegron patent litigation with Astellas by paying $120 million

Zydus Lifesciences has agreed to wage Astellas Pharma $120 cardinal to settee the U.S. patent litigation with the second implicit generic bladder upset cause Mirabegron.

The institution and subsidiary Zydus Pharmaceuticals USA, Inc., person entered into a colony statement with Astellas successful narration to Astellas’ Myrbetriq (generic name: Mirabegron), Zydus said.

Under the agreement, Zydus volition wage Astellas an aggregate magnitude of $120 million. Additionally, it volition wage a prepaid per portion licensing interest connected units of Zydus’ generic Mirabegron sold successful the U.S. from the day of colony statement till September 2027. Other presumption and conditions of the statement stay confidential, Zydus said.

The statement concludes each litigation betwixt Astellas and the 2 companies relating to Myrbetriq and Mirabegron and enables Zydus to proceed selling its generic Mirabegron successful the U.S., it said.

In April 2025, the United States District Court for the District of Delaware connected a lawsuit filed by Astellas against Zydus pertaining to the validity of a U.S. patent had passed an bid successful favour of the innovator. Infringement of the patent, damages and immoderate further invalidity theories volition beryllium litigated astatine a consolidated assemblage proceedings successful 2026, Zydus had said successful a filing then.

Earlier this week, another Indian generic drugmaker Lupin had announced the signing of a settlement and licence statement with Astellas to resoluteness their pending litigation. Under the statement Lupin volition beryllium paying $90 cardinal to Astellas and get to proceed selling Mirabegron.